Latest From Servier SA
Liposomal chemotherapy drug Onivyde achieved a 44% response rate in second-line small cell lung cancer patients, providing preliminary validation of its ability to improve outcomes in the hard-to-treat disease.
Private Company Edition: ARM's Q2 report shows a 38% decline in financings, but venture capital and upfront fees from deals were robust. Also, Servier raises $405m in the US, Frequency closes a $62m series C and VenatoRx accesses US government cash.
Deal Watch: Celgene Reworks Alliance With Jounce, Gaining Global Rights To Macrophage-Targeting Candidate
Revised agreement of 2016 collaboration returns all vopratelimab rights to Jounce. Gilead fortifies antiviral pipeline in deals with Novartis, Durect.
The French firm has handed back rights to MacroGenics’ lead DART candidate flotetuzumab. Undaunted, MacroGenics is forging ahead with clinical development including in combination use, while the market awaits a filing and license deal for its lead product margetuximab.
- Therapeutic Areas
- Metabolic Disorders
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Western Europe
- Company Type
- Midsize European
- Parent & Subsidiaries
- Servier SA
- Senior Management
Olivier Laureau, CEO
Emmanuel Canet, Sr. EVP, R&D
- Contact Info
Phone: (33) 55 72 60 00
35 rue de Verdun
Suresnes Cedex, 92284
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.